Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study

Autor: Christiane Susini, Véronique Moullart, Christian Duhamel, Rachida Lebtahi, Jean Claude Barbare, Séverine Hommel, Alexis Hugentobler, Eric Nguyen-Khac, Jean Louis Dupas, Thomas Aparicio, B. Tramier, Céline Lobry, Jean Paul Joly, Isabelle Ollivier, Jean François Cadranel
Přispěvatelé: Service d'Hépato-Gastroentérologie, CHU Amiens-Picardie, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'hépato-gastro-entérologie, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Nucléaire [Amiens], Service de médecine nucléaire [CHU Caen], Service de Médecine Nucléaire [Paris 18eme], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biologie et Pathologie Digestive, IFR 31 Louis Bugnard (IFR 31), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Hospitalier du Havre, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), CH Laennec de Creil, Service d'Hépato-Gastroentérologie CH Compiègne, CH COMPIEGNE, Service de Biostatistiques, Simon, Marie Francoise, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN)
Rok vydání: 2009
Předmět:
Adult
Male
Cancer Research
medicine.medical_specialty
Cirrhosis
Carcinoma
Hepatocellular
Octreotide
Scintigraphy
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Internal medicine
parasitic diseases
medicine
[SDV.BBM] Life Sciences [q-bio]/Biochemistry
Molecular Biology
Somatostatin receptor 2
Humans
[SDV.BBM]Life Sciences [q-bio]/Biochemistry
Molecular Biology
Receptors
Somatostatin
Receptor
Radionuclide Imaging
030304 developmental biology
Aged
Neoplasm Staging
Pharmacology
Prothrombin time
Aged
80 and over
0303 health sciences
medicine.diagnostic_test
Somatostatin receptor scintigraphy
business.industry
Indium Radioisotopes
Liver Neoplasms
Middle Aged
medicine.disease
Immunohistochemistry
3. Good health
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Multivariate Analysis
Molecular Medicine
France
Radiopharmaceuticals
Nuclear medicine
business
Somatostatin
medicine.drug
Zdroj: Cancer Biology and Therapy
Cancer Biology and Therapy, Taylor & Francis, 2009, 8 (21), pp.2033-9
Cancer Biology and Therapy, 2009, 8 (21), pp.2033-9
ISSN: 1555-8576
1538-4047
Popis: International audience; BACKGROUND: Somatostatin receptor scintigraphy (SRS) has been reported for receptor (SSTR) screening in advanced hepatocarcinoma (aHC) prior to somatostatin analogue treatment. AIMS: To evaluate SSTR screening with SRS in aHC patients. RESULTS: Seventy aHC patients (63 men) aged 65 +/- 11 y were included, with alcohol, viral or other causes cirrhosis in 35 (50%), 23 (33%), 12 (17%) cases respectively. CLIP score was 2.7 +/- 1.7, with more than three nodules in 37 (53%) cases. Largest nodule measured 7.6 +/- 4.5 cm. Median alpha-fetoprotein was 574 UI/mL. SRS was positive in 25/70 (35.7%) livers and 7/17 (41.2%) metastatic sites. Positive SRS patients differed from others for tumor size (9.2 +/- 4 vs. 6.7 +/- 4.6 cm, p = 0.03), prothrombin time (PT) (75.2 +/- 15.2 vs. 61.9 +/- 19%, p = 0.005), albumin (34.1 +/- 5.9 vs. 30.5 +/- 7.2 g/L, p = 0.04) and Child-Pugh (6.7 +/- 1.8 vs. 7.7 +/- 2.3, p = 0.04). After multivariate analysis, only PT was associated with positive SRS (p = 0.028). Immunohistochemistry was positive for SSTR2s in 6/7 tumors (SRS uptake in 5/6 cases). METHODS: SRS was performed prior treatment, with images at 4, 24 and 48 h. For seven tumors, SSTR2 subtype was detected immunohistochemically. CONCLUSIONS: In advanced hepatocarcinoma, we report SRS uptake in 35.7% of livers and 41.2% of metastatic sites. SRS value in screening patients for somatostatin analogue treatment remains to be assessed.
Databáze: OpenAIRE
Externí odkaz: